Loading
Cancer, Hypoxia, and Metabolism / Immune Cells in Cancer / Ferroptosis and Cancer Prognosis · Journal article
Experimental & Molecular Medicine · August 5, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic investigation of how itaconate, derived from macrophage-to-myofibroblast transition, promotes lung cancer bone metastasis via an HSPA8–ATF4–PSAT1 signalling axis, demonstrated in integrated omics profiling and animal models. The work identifies a potential therapeutic target (HSPA8 or PSAT1) and shows proof-of-concept that blocking this pathway in mice reduces tumour burden and prolongs survival, but lacks human efficacy data and does not compare to established clinical therapies.
Integrated mechanistic profiling (metabolomics, transcriptomics, ubiquitination proteomics) with CRISPR-Cas9 knockout validation and animal model. Lung cancer bone metastasis model (species and detailed eligibility criteria not specified in abstract). Intervention: Adeno-associated virus-delivered PSAT1 short hairpin RNA or cell-penetrating itaconate antagonist.
Macrophage-to-myofibroblast transition generates cancer-associated fibroblasts that secrete elevated itaconate levels, significantly accelerating tumour growth Itaconate directly targets HSPA8, promoting its ubiquitination and proteasomal degradation, which releases ATF4 for nuclear translocation ATF4 binds the PSAT1 promoter to upregulate its expression as part of the pro-tumorigenic metabolic axis
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If the HSPA8–ATF4–PSAT1 axis is confirmed in human lung cancer bone metastasis, selective inhibitors of HSPA8 or PSAT1 could represent novel immunometabolic targets. However, translation to clinical use requires human validation, dose–response studies, and head-to-head trials against current metastatic therapies.
Mechanistic study in animal models of a proposed metabolic axis in lung cancer bone metastasis; no clinical outcome data, human efficacy trials, or direct comparison to standard therapy reported.
As stated by the source record.
If the HSPA8–ATF4–PSAT1 axis is confirmed in human lung cancer bone metastasis, selective inhibitors of HSPA8 or PSAT1 could represent novel immunometabolic targets. However, translation to clinical use requires human validation, dose–response studies, and head-to-head trials against current metastatic therapies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Lung cancer bone metastasis carries a poor prognosis, yet the metabolic determinants driving tumour-stroma crosstalk remain largely elusive. Despite extensive investigations into itaconate, a prominent immunometabolite implicated in macrophage polarization, the precise mechanisms by which it modulates bone metastasis remain unresolved. Integrating metabolomics and transcriptomics profiling, the molecular landscape of lung cancer bone metastasis is delineated and the mechanistic role of itaconate is uncovered. Further ubiquitination proteomics of tumour cells and CRISPR-Cas9-mediated knockout of the gene encoding immune-responsive gene 1 (IRG1) confirmed the results in an animal model of lung cancer bone metastasis. The macrophage-to-myofibroblast transition generated cancer-associated fibroblasts that secreted elevated levels of itaconate, significantly accelerating tumour growth. A drug affinity responsive target stability screening pinpointed heat shock protein family A member 8 (HSPA8) as a direct molecular target of itaconate. Mechanistically, itaconate promoted HSPA8 ubiquitination and subsequent proteasomal degradation, thereby releasing activated transcription factor 4 (ATF4) from cytosolic sequestration. Liberated ATF4 translocated to the nucleus, where it bound the promoter region of phosphoserine aminotransferase 1 (PSAT1) to upregulate its expression. In vivo validation demonstrated that administration of adeno-associated virus-delivered PSAT1 short hairpin RNA or of a cell-penetrating itaconate antagonist significantly reduced tumour burden and prolonged survival. Our findings elucidate an unappreciated metabolic reprogramming axis in lung cancer bone metastases: macrophage-to-myofibroblast transition-derived itaconate alleviated cytoplasmic sequestration of ATF4 via HSPA8 ubiquitination, thereby activating its transcriptional target PSAT1. This mechanism converts immunometabolic byproducts into pro-tumorigenic signals that enhance bone metastasis. Notably, the HSPA8-ATF4-PSAT1 axis was identified as a key regulatory pathway governing metabolic reprogramming, thereby establishing a translational framework for targeting immunometabolic crosstalk in bone metastasis therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.